Keyphrases
Immunogenicity
100%
Inborn Errors of Immunity
100%
Coronavirus Disease 2019 Vaccine
100%
Pfizer-BioNTech
100%
Specific Antibodies
50%
Cellular Immune Response
50%
COVID-19
50%
Israel
25%
Receptor Binding
25%
Medical Personnel
25%
Second Dose
25%
Elderly Patients
25%
Cellular Response
25%
Adverse Events
25%
Elderly People
25%
Peripheral Blood Mononuclear Cells
25%
Primary Immunodeficiency
25%
Converting Enzyme
25%
Humoral Response
25%
RNA-based
25%
Adult Patients
25%
Interleukin-2
25%
Receptor-binding Domain
25%
T Cell Response
25%
Humoral Immune Response
25%
Antibody Titer
25%
Mass Vaccination
25%
Patients with Chronic Diseases
25%
Combined Immunodeficiency
25%
ELISPOT
25%
Immune Dysregulation
25%
Secondary Immunodeficiency
25%
CoV-2
25%
Primary Antibody Deficiency
25%
Immunoglobulin Replacement Therapy (IgRT)
25%
Medicine and Dentistry
Immunogenicity
100%
COVID-19
100%
Primary Immunodeficiency
100%
Immune Deficiency
40%
Humoral Immunity
40%
Cellular Immunity
40%
Antibodies
40%
Antibody Response
40%
Receptor Binding
40%
Secretion (Process)
20%
Immunoglobulin
20%
Population
20%
Clinician
20%
Adverse Event
20%
Peripheral Blood Mononuclear Cell
20%
Substitution Therapy
20%
Dipeptidyl Carboxypeptidase
20%
Chronic Disease
20%
Mass Immunization
20%
T-Cell Response
20%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Immune Dysregulation
20%
Combined Immunodeficiencies
20%
Humoral Immune Deficiency
20%
Immunology and Microbiology
Vaccine Efficacy
100%
Immunogenicity
100%
Primary Immunodeficiency
100%
COVID-19
100%
Monospecific Antibody
33%
Immunodeficiency
33%
Adoptive Immunity
33%
Humoral Immunity
33%
Receptor Binding
33%
Antibody Response
33%
Spike
16%
Population
16%
Secretion (Process)
16%
Intravenous Immunoglobulin
16%
T Cell
16%
Blood Plasma
16%
Vaccination Policy
16%
Antibody Titer
16%
Peripheral Blood Mononuclear Cell
16%
Combined Immunodeficiencies
16%
Immune Dysregulation
16%
Humoral Immune Deficiency
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Immunogenicity
100%
Coronavirinae
100%
Receptor
40%
Immune Deficiency
40%
Antibodies
40%
Replacement Therapy
20%
Adverse Event
20%
Dipeptidyl Carboxypeptidase
20%
Chronic Disease
20%
Vaccination Policy
20%
Immunoglobulin
20%
SARS Coronavirus
20%
Immune Dysregulation
20%
Combined Immunodeficiencies
20%
Humoral Immune Deficiency
20%